StockNews.AI
CBLL
StockNews.AI
189 days

Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

1. Ceribell to announce Q4 and full-year 2024 financial results on Feb 25. 2. Company's innovative EEG system enhances patient care in acute settings. 3. Ceribell's FDA-cleared technology aids in rapid seizure diagnosis.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could signal growth; positive innovations typically boost investor confidence.

How important is it?

The announcement of financial results and innovative product positioning are crucial for CBLL's future valuation.

Why Short Term?

Immediate market reaction expected to the financial results announcement.

Related Companies

CBLL
February 11, 2025 16:05 ET  | Source: Ceribell SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 25, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 3782735. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn. Investor ContactBrian Johnston or Laine MorganGilmartin GroupInvestors@ceribell.com Media ContactCorrie RosePress@ceribell.com

Related News